MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

Search

PerkinElmer Inc

Slēgts

SektorsVeselības aprūpe

0

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

Max

Galvenie mērījumi

By Trading Economics

Ienākumi

95M

Pārdošana

45M

729M

P/E

Sektora vidējais

46

63.778

EPS

1.42

Dividenžu ienesīgums

0.26

Peļņas marža

12.976

Darbinieki

11,000

EBITDA

7.4M

223M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

+28.04% upside

Dividendes

By Dow Jones

Dividenžu ienesīgums

Sektora vidējais

0.26%

2.39%

Nākamie ieņēmumi

2025. g. 28. apr.

Nākamais dividenžu datums

2025. g. 9. maijs

Nākamais Ex dividenžu datums

2025. g. 18. apr.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-2.9B

13B

Iepriekšējā atvēršanas cena

0

Iepriekšējā slēgšanas cena

0

Ziņu noskaņojums

By Acuity

33%

67%

106 / 386 Rangs Healthcare

PerkinElmer Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 2. apr. 23:55 UTC

Karstas akcijas

Stocks to Watch: RH, Nike, Dollar Tree, Apple

2025. g. 2. apr. 22:50 UTC

Galvenie tirgus virzītāji

E.l.f. Beauty, Estee Lauder, Coty Shares Fall on Reciprocal Tariffs Hit

2025. g. 2. apr. 21:08 UTC

Peļņas

RH 4Q Revenue Misses Guidance, Looks to Offset Reciprocal Tariffs -- Update

2025. g. 2. apr. 21:00 UTC

Peļņas

RH 4Q Revenue Misses Guidance, Looks to Offset Reciprocal Tariffs

2025. g. 2. apr. 23:56 UTC

Tirgus saruna

Gold Rises as Trump's Tariffs Enhance Safe-Haven Appeal -- Market Talk

2025. g. 2. apr. 23:44 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2025. g. 2. apr. 23:44 UTC

Tirgus saruna

Nikkei Likely to Fall After U.S. Tariff Plan -- Market Talk

2025. g. 2. apr. 23:44 UTC

Top Ziņas

Some GOP Senators Break With Trump to Reject Canada Tariffs -- WSJ

2025. g. 2. apr. 23:32 UTC

Tirgus saruna

Market Talk Roundup: Latest on U.S. Politics

2025. g. 2. apr. 23:32 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 2. apr. 23:32 UTC

Tirgus saruna

Trump's Tariffs on Australia Conspicuously Unfriendly -- Market Talk

2025. g. 2. apr. 23:12 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2025. g. 2. apr. 23:12 UTC

Tirgus saruna

Trump Tariff 'Blow Bigger Than We Expected,' Capital Economics Says -- Market Talk

2025. g. 2. apr. 23:10 UTC

Tirgus saruna

Canada, Mexico Get Short-Term Advantage From Trump's Tariff Moves -- Market Talk

2025. g. 2. apr. 23:09 UTC

Tirgus saruna

U.S. Effective Tariff Rate Highest in 131 Years -- Market Talk

2025. g. 2. apr. 23:09 UTC

Tirgus saruna

Market Talk Roundup: Latest on U.S. Politics

2025. g. 2. apr. 22:57 UTC

Tirgus saruna

Australia Spared Worst Of US Tariff Hikes -- Market Talk

2025. g. 2. apr. 22:56 UTC

Tirgus saruna

Market Talk Roundup: Latest on U.S. Politics

2025. g. 2. apr. 22:56 UTC

Tirgus saruna

US Equity Futures Down as Tariff Hikes Stoke Recession Fears -- Market Talk

2025. g. 2. apr. 22:43 UTC

Top Ziņas
Iegādes, apvienošanās, pārņemšana

AppLovin, Amazon Emerge as TikTok Bidders Ahead of Trump's Deadline, Sources Say -- 2nd Update

2025. g. 2. apr. 22:12 UTC

Tirgus saruna

Trump's Tariff Order May Set Path for New U.S.-Canada Pact -- Market Talk

2025. g. 2. apr. 21:48 UTC

Top Ziņas

The Stock Market Pain Is Just Getting Started. 'This is How You Sabotage the World's Economic Engine.' -- Barrons.com

2025. g. 2. apr. 21:41 UTC

Tirgus saruna

USD Reaction To Trump's Tariffs Limited So far -- Market Talk

2025. g. 2. apr. 21:17 UTC

Tirgus saruna

Market Talk Roundup: Latest on U.S. Politics

2025. g. 2. apr. 21:17 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 2. apr. 21:17 UTC

Tirgus saruna

Mexican Peso Gains as Worst Tariff Fears Avoided -- Market Talk

2025. g. 2. apr. 21:04 UTC

Top Ziņas

Trump's Tariffs Could Blow Up Big Pharma's Tax Shelter -- Heard on the Street -- Update

2025. g. 2. apr. 21:03 UTC

Tirgus saruna

Treasury Yields, Dollar, Stock Futures Fall as Markets Digest Tariffs -- Market Talk

2025. g. 2. apr. 20:53 UTC

Peļņas

Kaiser Aluminum Changes Method From Last-In, First-Out to Weighted Avg Cost Effective Jan. 1, 2025

2025. g. 2. apr. 20:52 UTC

Peļņas

Kaiser Aluminum Changes Inventory Acctg Methodology

Salīdzinājums

Cenas izmaiņa

PerkinElmer Inc Prognoze

Cenas mērķis

By TipRanks

28.04% augšup

Prognoze 12 mēnešiem

Vidējais 136.64 USD  28.04%

Augstākais 145 USD

Zemākais 120 USD

Pamatojoties uz 11 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi PerkinElmer Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

11 ratings

7

Pirkt

4

Turēt

0

Pārdot

Noskaņojums

By Acuity

106 / 386 Rangs Veselības aprūpe

Ziņu noskaņojums

Liecība "Buļļu" tendencei

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Virs vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par PerkinElmer Inc

Revvity, Inc. provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, BACS-on-Beads, BIOCHIPs, Bioo Scientific,BoBs , chemagic, Chitas, DELFIA, DELFIA Xpress, DOPlify, EONIS, EUROArray, EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, explorer, Fontus, Genoglyphix, GSP, Haoyuan, IDS, IDS-i10 IDS-i10T, IDS-iSYS, iLab, iQ, JANUS, LabChip, LifeCycle, LimsLink, Migele, MultiPROBE, NEXTFLEX, NextPrep, Pannoramic, Panthera Puncher, PG-Seq, PGFind PKamp, PreNAT II, Prime, Protein Clear, ProteinEXact, QSigh, QuantiVac, RONIA, Sciclone, SimplicityChrom, Specimen Gate,Superflex, Symbio, T-SPOT, Touch, Twister, Vanadis, VariSpec, ViaCord VICTOR 2D, and Zephyr brand name. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.